497 related articles for article (PubMed ID: 15530689)
1. Immune responses and protective efficacy in ponies immunised with an equine influenza ISCOM vaccine containing an 'American lineage' H3N8 virus.
Crouch CF; Daly J; Hannant D; Wilkins J; Francis MJ
Vaccine; 2004 Dec; 23(3):418-25. PubMed ID: 15530689
[TBL] [Abstract][Full Text] [Related]
2. The use of a systemic prime/mucosal boost strategy with an equine influenza ISCOM vaccine to induce protective immunity in horses.
Crouch CF; Daly J; Henley W; Hannant D; Wilkins J; Francis MJ
Vet Immunol Immunopathol; 2005 Dec; 108(3-4):345-55. PubMed ID: 16098611
[TBL] [Abstract][Full Text] [Related]
3. Protection, systemic IFNgamma, and antibody responses induced by an ISCOM-based vaccine against a recent equine influenza virus in its natural host.
Paillot R; Grimmett H; Elton D; Daly JM
Vet Res; 2008; 39(3):21. PubMed ID: 18252187
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a canarypox-vectored recombinant vaccine expressing the hemagglutinin gene of equine influenza H3N8 virus in the protection of ponies from viral challenge.
Minke JM; Toulemonde CE; Coupier H; Guigal PM; Dinic S; Sindle T; Jessett D; Black L; Bublot M; Pardo MC; Audonnet JC
Am J Vet Res; 2007 Feb; 68(2):213-9. PubMed ID: 17269889
[TBL] [Abstract][Full Text] [Related]
5. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge.
Breathnach CC; Clark HJ; Clark RC; Olsen CW; Townsend HG; Lunn DP
Vaccine; 2006 Feb; 24(8):1180-90. PubMed ID: 16194586
[TBL] [Abstract][Full Text] [Related]
6. The first safe inactivated equine influenza vaccine formulation adjuvanted with ISCOM-Matrix that closes the immunity gap.
Heldens JG; Pouwels HG; Derks CG; Van de Zande SM; Hoeijmakers MJ
Vaccine; 2009 Sep; 27(40):5530-7. PubMed ID: 19607950
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and duration of immunity of a combined equine influenza and equine herpesvirus vaccine against challenge with an American-like equine influenza virus (A/equi-2/Kentucky/95).
Heldens JG; Pouwels HG; van Loon AA
Vet J; 2004 Mar; 167(2):150-7. PubMed ID: 14975389
[TBL] [Abstract][Full Text] [Related]
8. ISCOM-matrix-based equine influenza (EIV) vaccine stimulates cell-mediated immunity in the horse.
Paillot R; Prowse L
Vet Immunol Immunopathol; 2012 Jan; 145(1-2):516-21. PubMed ID: 22178272
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a whole inactivated EI vaccine against a recent EIV outbreak isolate and comparative detection of virus shedding.
Paillot R; Prowse L; Donald C; Medcalf E; Montesso F; Bryant N; Watson J; Jeggo M; Elton D; Newton R; Trail P; Barnes H
Vet Immunol Immunopathol; 2010 Aug; 136(3-4):272-83. PubMed ID: 20400185
[TBL] [Abstract][Full Text] [Related]
10. Formulation with CpG ODN enhances antibody responses to an equine influenza virus vaccine.
Lopez AM; Hecker R; Mutwiri G; van Drunen Littel-van den Hurk S; Babiuk LA; Townsend HG
Vet Immunol Immunopathol; 2006 Nov; 114(1-2):103-10. PubMed ID: 16950519
[TBL] [Abstract][Full Text] [Related]
11. Antibody and IFN-gamma responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus.
Paillot R; Kydd JH; Sindle T; Hannant D; Edlund Toulemonde C; Audonnet JC; Minke JM; Daly JM
Vet Immunol Immunopathol; 2006 Aug; 112(3-4):225-33. PubMed ID: 16621023
[TBL] [Abstract][Full Text] [Related]
12. Local and systemic isotype-specific antibody responses to equine influenza virus infection versus conventional vaccination.
Nelson KM; Schram BR; McGregor MW; Sheoran AS; Olsen CW; Lunn DP
Vaccine; 1998 Aug; 16(13):1306-13. PubMed ID: 9682395
[TBL] [Abstract][Full Text] [Related]
13. Onset and duration of immunity to equine influenza virus resulting from canarypox-vectored (ALVAC) vaccination.
Soboll G; Hussey SB; Minke JM; Landolt GA; Hunter JS; Jagannatha S; Lunn DP
Vet Immunol Immunopathol; 2010 May; 135(1-2):100-107. PubMed ID: 20018384
[TBL] [Abstract][Full Text] [Related]
14. Evidence supporting the inclusion of strains from each of the two co-circulating lineages of H3N8 equine influenza virus in vaccines.
Daly JM; Yates PJ; Newton JR; Park A; Henley W; Wood JL; Davis-Poynter N; Mumford JA
Vaccine; 2004 Sep; 22(29-30):4101-9. PubMed ID: 15364463
[TBL] [Abstract][Full Text] [Related]
15. Duration of immunity induced by an equine influenza and tetanus combination vaccine formulation adjuvanted with ISCOM-Matrix.
Heldens JG; Pouwels HG; Derks CG; Van de Zande SM; Hoeijmakers MJ
Vaccine; 2010 Oct; 28(43):6989-96. PubMed ID: 20728523
[TBL] [Abstract][Full Text] [Related]
16. Is there a benefit from an early booster vaccination in the control of equine influenza?
Heldens JG; van Loon AA; van de Zande S
Vet J; 2007 Nov; 174(3):592-8. PubMed ID: 17560150
[TBL] [Abstract][Full Text] [Related]
17. Vaccine failure caused an outbreak of equine influenza in Croatia.
Barbic L; Madic J; Turk N; Daly J
Vet Microbiol; 2009 Jan; 133(1-2):164-71. PubMed ID: 18632226
[TBL] [Abstract][Full Text] [Related]
18. A vectored equine herpesvirus type 1 (EHV-1) vaccine elicits protective immune responses against EHV-1 and H3N8 equine influenza virus.
Van de Walle GR; May MA; Peters ST; Metzger SM; Rosas CT; Osterrieder N
Vaccine; 2010 Jan; 28(4):1048-55. PubMed ID: 19897066
[TBL] [Abstract][Full Text] [Related]
19. A comparison of antibody responses to commercial equine influenza vaccines following primary vaccination of Thoroughbred weanlings--a randomised blind study.
Gildea S; Arkins S; Walsh C; Cullinane A
Vaccine; 2011 Nov; 29(49):9214-23. PubMed ID: 21983355
[TBL] [Abstract][Full Text] [Related]
20. Safety, efficacy, and immunogenicity of a modified-live equine influenza virus vaccine in ponies after induction of exercise-induced immunosuppression.
Lunn DP; Hussey S; Sebing R; Rushlow KE; Radecki SV; Whitaker-Dowling P; Youngner JS; Chambers TM; Holland RE; Horohov DW
J Am Vet Med Assoc; 2001 Mar; 218(6):900-6. PubMed ID: 11294315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
